Tomino Carlo, Ilari Sara, Solfrizzi Vincenzo, Malafoglia Valentina, Zilio Guglielmo, Russo Patrizia, Proietti Stefania, Marcolongo Federica, Scapagnini Giovanni, Muscoli Carolina, Rossini Paolo Maria
Scientific Direction, IRCCS San Raffaele Roma, 00166 Rome, Italy.
Department of Health Science, Institute of Research for Food Safety & Health (IRC-FSH), University "Magna Graecia" of Catanzaro, 88201 Catanzaro, Italy.
Pharmaceuticals (Basel). 2021 Apr 1;14(4):305. doi: 10.3390/ph14040305.
Mild cognitive impairment (MCI) and dementia are clinically prevalent in the elderly. There is a high risk of cognitive decline in patients diagnosed with MCI or dementia. This review describes the effectiveness of Ginkgo biloba leaf special extract EGb 761 for the treatment of dementia syndromes and EGb 761 combination therapy with other medications for symptomatic dementia. This drug has shown convincing results, improving cognitive function, neuropsychiatric symptoms and consequent reduction of caregiver stress and maintenance of autonomy in patients with age-related cognitive decline, MCI and mild to moderate dementia. Currently, there is little evidence to support the combination therapy with anti-dementia drugs and, therefore, more evidence is needed to evaluate the role of EGb 761 in mixed therapy.
轻度认知障碍(MCI)和痴呆在老年人中临床常见。被诊断为MCI或痴呆的患者存在认知功能下降的高风险。本综述描述了银杏叶特殊提取物EGb 761治疗痴呆综合征的有效性,以及EGb 761与其他药物联合治疗症状性痴呆的情况。该药物已显示出令人信服的结果,可改善年龄相关性认知功能下降、MCI和轻度至中度痴呆患者的认知功能、神经精神症状,进而减轻照料者压力并维持患者自主性。目前,几乎没有证据支持抗痴呆药物的联合治疗,因此,需要更多证据来评估EGb 761在联合治疗中的作用。